AAM
SAGE

Advisors Asset Management’s Sage Therapeutics SAGE Stock Holding History

Advisors Asset Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-232
Closed -$14.2K – 1547
2020
Q3 		$14.2K Sell
232
-28
-11% -$1.42K ﹤0.01% 1475
2020
Q2 		$10.8K Sell
260
-7
-3% -$254 ﹤0.01% 1490
2020
Q1 		$7.67K Sell
267
-6
-2% -$347 ﹤0.01% 1435
2019
Q4 		$19.7K Buy
273
+1
+0.4% +$123 ﹤0.01% 1462
2019
Q3 		$38.2K Sell
272
-1,887
-87% -$316K ﹤0.01% 1422
2019
Q2 		$395K Buy
2,159
+1,643
+318% +$280K 0.01% 1048
2019
Q1 		$82.1K Sell
516
-10
-2% -$1.45K ﹤0.01% 1353
2018
Q4 		$50K Sell
526
-38
-7% -$4.35K ﹤0.01% 1431
2018
Q3 		$80K Buy
564
+28
+5% +$4.32K ﹤0.01% 1385
2018
Q2 		$84K Buy
+536
New +$84.1K ﹤0.01% 1362

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisors Asset Management's SAGE Position: Q4 2020 in Review

Advisors Asset Management sold out of Sage Therapeutics (SAGE) in Q4 2020, closing a stake of 232 shares — an estimated $14.2K sold.

Advisors Asset Management first reported a position in SAGE in Q2 2018 and held it in 10 quarters. The position peaked at $395K in Q2 2019. 249 funds tracked by Wall St. Rank hold SAGE as of Q4 2020.

  • Advisors Asset Management reported no remaining Sage Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Advisors Asset Management sold 232 Sage Therapeutics shares in Q4 2020, an estimated $14.2K.
  • Advisors Asset Management first reported a position in Sage Therapeutics in Q2 2018 and held it in 10 quarters.
  • Advisors Asset Management's Sage Therapeutics position peaked at $395K in Q2 2019.
  • 249 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2020.

Based on Advisors Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.